This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Celgene's New Multiple Myeloma Drug Is Kicking Amgen's Ass

CELG ChartCELG data by YCharts

SUMMIT, NJ (TheStreet) -- Celgene (CELG) issued another "beat and raise" earnings report for the third quarter earnings -- pretty much standard operating procedure these days -- but take a look at the company's new multiple myeloma drug Pomalyst.

With $90 million in third-quarter sales, Pomalyst is kicking ass just three quarters into the launch.

Healthcare portfolio manager Ian Estepan picked up the significance in a tweet this morning:

Kyprolis is the multiple myeloma drug acquired by Amgen (AMGN) in the $10 billion Onyx Pharmaceuticals deal. Both Kyprolis and Pomalyst are approved to treat patients with multiple myeloma that no longer responds to other drugs.

In other words, the two drugs compete for the same multiple myeloma patients, but so far, doctors seem to prefer Pomalyst over Kyprolis.

Kyprolis sales in the third quarter: $65 million, a touch weaker than Wall Street consensus.

The $90 million in Pomalyst sales for the third quarter trounced Wall Street expectations by $16 million, according to JP Morgan analyst Geoff Meacham.

Pomalyst is approved in the U.S. and Europe while Kyprolis is sold only stateside, but even Pomalyst U.S. sales of $77 million in the September quarter beat Kyprolis by a comfortable margin.

As Estepan points outs, Kyprolis received FDA approval in July 2012 while Pomalyst was approved this past February (European approval came in August.)

With less time on the market, Pomalyst is beating its closest competitor, which bodes well for Celgene as the company seeks to expand the drug's use into earlier stage multiple myeloma patients.

-- Reported by Adam Feuerstein in Boston.

Stock quotes in this article: CELG, AMGN 
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,262.56 +89.32 0.55%
S&P 500 1,842.98 +12.37 0.68%
NASDAQ 4,034.1610 +11.4670 0.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs